ArticleActa dermato-venereologica2025

Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic.

Masato MizuashiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.